Natco Pharma Limited Stock Revenue
| NATCOPHARM | 1,376 38.05 2.84% |
Natco Pharma Limited fundamentals help investors to digest information that contributes to Natco Pharma's financial success or failures. It also enables traders to predict the movement of Natco Stock. The fundamental analysis module provides a way to measure Natco Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Natco Pharma stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 40 B | 42 B |
Natco | Revenue |
Natco Pharma Limited Company Revenue Analysis
Natco Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Natco Pharma Revenue | 40.02 B |
Most of Natco Pharma's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Natco Pharma Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Natco
Projected quarterly revenue analysis of Natco Pharma Limited provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Natco Pharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Natco Pharma's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Natco Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Natco Pharma Limited reported 40.02 B of revenue. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all India stocks is notably lower than that of the firm.
Natco Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Natco Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Natco Pharma could also be used in its relative valuation, which is a method of valuing Natco Pharma by comparing valuation metrics of similar companies.Natco Pharma is currently under evaluation in revenue category among its peers.
Natco Fundamentals
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.19 | ||||
| Profit Margin | 0.43 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 223.82 B | ||||
| Shares Outstanding | 179.11 M | ||||
| Shares Owned By Insiders | 50.90 % | ||||
| Shares Owned By Institutions | 14.39 % | ||||
| Price To Book | 3.45 X | ||||
| Price To Sales | 5.40 X | ||||
| Revenue | 40.02 B | ||||
| Gross Profit | 20.54 B | ||||
| EBITDA | 18.8 B | ||||
| Net Income | 13.88 B | ||||
| Cash And Equivalents | 4.14 B | ||||
| Total Debt | 3.86 B | ||||
| Book Value Per Share | 399.14 X | ||||
| Cash Flow From Operations | 12.52 B | ||||
| Earnings Per Share | 108.66 X | ||||
| Target Price | 1343.09 | ||||
| Number Of Employees | 4.02 K | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 246.37 B | ||||
| Total Asset | 69.06 B | ||||
| Retained Earnings | 44.66 B | ||||
| Working Capital | 30.51 B | ||||
| Annual Yield | 0 % | ||||
| Net Asset | 69.06 B | ||||
| Last Dividend Paid | 1.25 |
About Natco Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Natco Pharma Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Natco Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Natco Pharma Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Natco Stock
Natco Pharma financial ratios help investors to determine whether Natco Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Natco with respect to the benefits of owning Natco Pharma security.